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Abstract 
Controlled human infection trials (CHI), in which healthy volunteers are experimentally infected, can 
accelerate the development of novel drugs and vaccines for infectious diseases of global importance. 
The use of CHI models is expanding from ~60 studies in the 1970’s to more than 120 publications in 
this decade, primarily for influenza, rhinovirus and malaria. CHI trials provided landmark data for 
several registered drugs and vaccines and have generated unprecedented scientific insights. Because 
of their invasive nature, CHI studies demand critical ethical review according to established 
frameworks. CHI-associated serious adverse events are rarely reported. Novel CHI models are in 
need of standardized safety data from comparable CHI models to facilitate evidence-based risk 
assessments and funds to produce challenge inoculum according to regulatory requirements. 
Advances such as the principle of controlled colonisation, the expansion of models to endemic areas 
and the use of genetically attenuated strains will further broaden the CHI horizon.  
 
Introduction 
Controlled human infections (CHI), through the transfer of body fluid such as serum,1 respiratory 
secretions2 or faecal filtrates3 laid the foundation for infectious disease research in the 17th century. 
Unparalleled human experimentation led to the identification of causative organisms (norovirus,3 
influenza,2 dengue,4 sarcocystis5), not only proving Koch’s postulates, but also providing an 
opportunity to study incubation periods and clinical disease. Important discoveries were made such 
as the identification of toxins in causing diarrhoeal disease following instillation of Vibrio cholera 
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culture broth in volunteers in 1966.6 Whilst the ethics of these initial studies were often 
questionable, the realization that they provided a core platform for the study of infections, has 
resulted in the increased use of CHI models in the past decades. Ethical frameworks have been 
developed and rigorous independent review boards assess risks and benefits. The aims of the CHI 
studies are moving from exploratory and descriptive ones to trials that take a central position in the 
vaccine and drug development pipeline.7 CHI trials often act as a gatekeeper for proceeding to field 
efficacy trials, although in exceptional cases, may be accepted as proof-of-efficacy in Phase 3 clinical 
development.8 Each CHI model has been designed with specific inocula, endpoints or clinical 
procedures as a fit-for-purpose model (table 1). The efforts of developing novel CHI models and the 
exploitation of existing CHI models in the product development pipeline has been endorsed by large 
funders such as the Bill and Melinda Gates Foundation, the Wellcome Trust and the UK Medical 
Research Council, who have dedicated funds to CHI models. CHI studies, by allowing preliminary 
efficacy testing in 10-100 participants, are cheaper compared to phase 2 and 3 clinical trials in 
endemic areas that often require sample sizes ranging from hundreds to 100,000 participants. In 
addition, CHI studies allow for testing of a large number of products, minimize the risk of late clinical 
failure and reducing unnecessary exposure of (vulnerable) populations to interventions (figure 1).  
In CHI trials biomarkers, protective responses and mechanisms of disease can be studied, which 
ultimately feed back into the product development pipeline to improve the next generation of 
medicines. Novel technological advances such as –omics tools are applied to identify risk factors 
such as diet, microbiome, co-infections or genetic background using complex multiparametric 
analyse. Pathogens are altered by genetic modification in order to identify key virulence genes 
(NCT03067961) or provide less virulent challenge inocula which can allow for clinically less severe 
CHI models.9 In this review, we provide an overview of the active CHI models, discuss their 
contribution to biomedical science and risk some predictions of what can be expected in this 
dynamic field in the future.  
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Ethical considerations 
The son of Edward Jenner’s gardener has become the historic symbol of CHI when he was inoculated 
with cowpox in 1796. Other famous examples are infection of Macdonalds’ children with pertussis, 
the mentally retarded children at Willowbrook State school in New York with hepatitis virus10 and 
malaria infections in Nazi Germany.11 Following these experimentations, the Nuremberg Code (1946) 
and the Declaration of Helsinki (1964) provide guidelines for the conduct of medical research 
involving humans including informed consent procedures. CHI studies raise ethical debate because 
they seemingly breach the “do no harm” principle. However, the purpose of the CHI trial is to benefit 
global population health.12 Nonetheless, CHI trials inherently carry a risk for participants. They can 
only be performed in treatable or self-limiting diseases where no irreversible pathology is known to 
occur.13 The risk of a serious adverse event (SAE) should be assessed independently from the risk of 
discomfort. CHI studies may target a certain degree of discomfort (e.g. cholera, malaria, typhoid), 
but this may not necessarily be serious. In essence, the ethical principles in CHI are similar to those 
applied in phase I trials where healthy volunteers put themselves at risk without the possibility of 
deriving direct benefit.12-14 Justification for these trials lies in the potential value of the foreseeable 
scientific advances which benefit society. Thus, the degree of risk which is believed acceptable 
depends largely on the perceived benefits.12 Formal limits to these risks have not been established, 
but some argue that they should be equal to the risks people would normally take in many areas of 
life.12 CHI trials may raise debate on the appropriate compensation of the trial subject, protecting 
public confidence and on the risk of spread of infections.15 Using quarantine to minimize the risk of 
spread of challenge agents should be carefully considered as it substantially increases discomfort to 
the trial subjects as well as adding to the costs of the trial. 
Considering the body of literature on CHI, reports of SAEs are rare. In influenza and malaria CHI, four 
possibly related SAEs have been reported in an estimated 6000 volunteers. An episode of elevated 
serum transaminase and dilated cardiomyopathy was recorded in influenza CHI,16,17 while two 
cardiac SAEs were reported in a Plasmodium falciparum CHI trial.18,19 The latter episodes might have 
been myocarditis, an known immunological complication in vaccinology.20 P. vivax CHI experienced a 
set-back when malaria relapses occurred in two volunteers, due to a previously unrecognized 
genetic polymorphism that hinders bioactivation of the curative drug primaquine21. However, five 
years of follow-up showed that none had further relapses.22 
The dynamic scientific context of CHI trials continues to fuel regulatory and ethical discussions. 
Current ethical debate involves the use of genetically modified organisms (GMOs) and in particular 
its containment, as well as the use of CHI in populations with increased risks or resource poor 
environments. For example, pneumococcus colonisation has been performed in elderly and 
asthmatics (DF, personal comm.), whereas rhinovirus CHI has been performed in mild-to-moderate 
asthma and COPD patients.23,24 In this case, the resulting rhinovirus infection was well tolerated 
despite enhanced respiratory symptoms and secondary bacterial infections requiring increased 
vigilance.25  
 
The transfer of CHI studies to areas where infections are endemic (e.g. malaria, typhoid, 
pneumococcal disease), will raise specific ethical issues such as cultural acceptance, appropriate 
remuneration and consent procedures7, which were addressed in a recent workshop in Blantyre, 
Malawi.26 The ability to study the infection in a population with different disease incidence, co-
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infections, environmental exposures, nutrition status and immune responses has obvious benefits 
for the product development pipeline. Needless to say, thorough capacity building of infrastructure, 
clinical expertise, institutional review boards, pharmacists and ethicists will be needed.  
 
CHI in product development 
The contribution of CHI studies to the development of novel vaccines has been championed by the 
Live Oral Cholera Vaccine CVD 103-HgR study in 197 healthy volunteers.8 CVD 103-HgR was licenced 
in several countries since 1993, but only recently in the US.27 Volunteers were challenged by 
ingestion of wild-type V. cholera and were monitored for the occurrence of moderate or severe 
diarrhoea. The vaccine showed 90% efficacy, which, together with a good safety profile, led to 
licensure by the FDA.8 CHI models have accelerated the development of vaccines or drugs for a 
number of infections and are increasingly being used as proof of principle by product developers and 
as gatekeepers for further investment by funders (figure 2A). Currently, the most practised CHI 
models are for malaria, influenza and rhinovirus (Figure 2A+C) and trials are generally small, e.g. 
between 20-100 volunteers are included in the trials (figure 2B).  
An important milestone achieved through CHI has been the licensure of the world’s first malaria 
vaccine based on the subunit circumsporozoite protein (CSP) from Plasmodium falciparum (Pf), 
which has recently gained EMA approval.28 Pivotal proof of concept data for this vaccine were 
generated almost 10 years ago in a series of CHI trials showing  cumulatively ~40% protective 
efficacy after challenge with Pf in adults.29 The CHI results were confirmed in a phase 3 trial, which 
showed a similar partial (~30%) efficacy in children in Africa.30 Malaria CHI also proved to be 
instrumental in identifying candidates with poor efficacy, saving time and efforts by halting their 
clinical development.31  
In the field of malaria, CHI has been driven by the development of continuous in vitro culture 
techniques for P. falciparum and the rearing of laboratory-infected Anopheles mosquitoes. 32,33  The 
salivary-gland parasites were attenuated by radiation and used to inoculate replication-deficient 
parasites into volunteers. Ground breaking results showed that full protective immunity to Pf could 
be induced by exposing volunteers to the bites of >1000 of these mosquitoes carrying radiation 
attenuated parasites.34 The next level in technological advance was the ability to produce aseptic, 
purified, cryopreserved sporozoites.35 This work has formed the foundation for the clinical 
development program of the live attenuated malaria vaccine (PfSPZ Vaccine), which is now given by 
intravenous injection of radiation-attenuated extracted, purified and cryopreserved sporozoites.36 In 
parallel, an even more potent vaccine has been developed based on the exposure of volunteers to 
live sporozoites under chloroquine prophylaxis (chemoattenuation) resulting in sterile immunity or 
100% protection.37,38  
The genetic diversity of the malaria parasite poses a major obstacle for vaccine and drug 
development. The availability of genetically diverse strains of Pf for CHI allows for an accelerated 
assessment of potential cross-strain immunity.39,40 In addition, the availability of clinical grade blood 
stage parasites41 or purified, vialed and cryopreserved sporozoites for injection (PfSPZ Challenge, 
Sanaria Inc.)42 mean that the malaria CHI model no longer relies on the production of mosquitoes at 
the clinical site. This facilitated the transfer of the malaria CHI model to novel sites, an important 
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step to enable phase 2a trials in endemic areas.43,44 In order to increase the array of available strains, 
controlled production of infected mosquitoes is currently being set up in several centres in Africa. 
In malaria drug development, CHI provided the first proof for efficacy of “old” antimalarial drugs 
such as paludrine45 but also novel antimalarials such as atovaquone/proguanil46, ferroquine,47 
artefenomel,48 griseofulvin, 49 or more recently DSM265.50,51 With the advent of molecular methods 
for detection of parasites as low as 5-20 per mL blood52 it is possible to carefully dissect parasite 
growth rates to determine drug and vaccine mechanisms of action. Recently, treatment with 
piperaquine during CHI blood stage malaria was shown to induce gametocytes, potentially adding a 
sexual stage Pf CHI model to the current portfolio.53 This may be an important platform to accelerate 
the development of transmission blocking vaccines, recently identified as a priority in the Malaria 
Vaccine Technology Roadmap.54 
The other frequently used model has been controlled influenza infection. Influenza CHI enabled the 
clinical testing of the first generation of influenza vaccines, which were based on infected and 
formalin inactivated allantoic fluid.55 Later, CHI trials led to the first registration of a live attenuated 
vaccine for influenza A.56 Immunological analysis showed that pre-inoculation hemagglutinin 
inhibition titre and particularly neuraminidase inhibition titres in healthy, unvaccinated volunteers, 
as well as pre-challenge CD4+ T-cell responses (not CD8+ cells) predict clinical outcome after CHI.57,58 
Building upon these immunological findings, a human monoclonal antibody targeting an influenza 
conserved epitope,59 a trivalent DNA vaccine60 and a viral vectored vaccine against conserved 
influenza antigens61 were all proven efficacious in influenza CHI, providing hopeful prospects for the 
development of cross-strain and long-lasting influenza vaccines.  
Influenza CHI have also played a central role in the FDA registration of the first influenza antiviral 
drug amantadine in 1966.62 Thereafter, studies showed efficacy of the amantadine analogue 
rimantadine63 (FDA approved in 1994) and a range of antivirals such as zanamivir, oseltamivir and 
preamivir.17,64-66 Influenza CHI is now applied to study the development of strains resistant to these 
novel antivirals as people are treated with increasing concentrations of the drug.67 In terms of 
respiratory infections, CHI has facilitated the development of drugs for other respiratory infections, 
such as respiratory syncytial virus.68  
Impressive progress has been booked in dengue vaccine development. The early down-selection of 
dengue vaccine candidates is imperative because antibody dependent enhancement of viral 
replication may pose vaccinees at risk of more severe disease, as was seen in  in a phase 3 study.69 
Recently, a live attenuated recombinant dengue vaccine (TV0003) showed complete protection in 
CHI70 and is now undergoing phase 3 evaluation in Brazil and Thailand (NCT02406729, 
NCT02332733). Remarkably, the dengue CHI model was developed as a result of the live attenuated 
dengue vaccine programme, where an insufficiently attenuated dengue strain (rDEN2Δ30) failed as 
vaccine candidate because it led to viremia and rash, this provided an opportunity for use as CHI.4 
CHI models have also been instrumental for a number of gastrointestinal infections. For example, 
the most advanced Norwalk virus vaccine, an intranasal VLP formulation, proved to be efficacious in 
two separate CHI studies.71,72 In Salmonella enterica serovar Typhi research, CHI allowed for the 
early benchmarking of novel vaccine candidates against the licenced Ty21a oral live attenuated 
vaccine.73 In enterotoxicogenic E. coli studies, the therapeutic effect of trimethoprim-
sulfamethoxazole was first documented in CHI studies.74 Multiple prophylactic and therapeutic 
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medicines have been tested in the ETEC CHI model, in which bismuth subsalicylate and an oral 
colicin E2 treated whole-cell vaccine, showed potential as effective prophylactics.75,76 
Despite the fact that CHI studies take a central role in the clinical development pipeline, formal 
guidelines on the use of such trials by developers on the licensure path are lacking. Last year, the 
WHO published a statement on the regulatory considerations for the use of controlled human 
infection trials in vaccine development.77 It is important that such position papers also highlight the 
limitation of CHI studies.  For example, inoculation routes may differ between natural infections and 
CHI trials,2 the trial population may not be similar to the population at risk, challenge strains may 
differ from natural infections, protective immune mechanism may not be universally applicable and 
the selection of susceptible adults without pre-existing immunity might reflect intrinsic vulnerability 
which may not hold true for the whole population. Despite these differences, the results obtained in 
CHI trials are generally confirmed in phase 2 efficacy trials. To our knowledge, there is no example of 
a vaccine or drug which failed in CHI and was found efficacious in later phase 2 or 3 field trials.  
The predictive value and reproducibility of CHI studies is highly dependent on the quality of the 
challenge material. The regulatory requirements for the production of this material may vary in 
different continents. Current regulatory environments have shown that increased control may not 
always be beneficial to the CHI models, which should preferably remain low cost and be flexible to 
accommodate changes in circulating strains (e.g. influenza) in order to remain clinically relevant. 
Therefore, consistent unifying quality control and assurance measures for challenge material are 
needed in order to balance safety and the costs of production. 
 
Novel CHI models in poverty-related and neglected diseases 
Because of the potential to reduce costs and time to registration, CHI models are particularly 
appealing for the development of products for resource-poor countries where infectious diseases 
are still responsible for considerable morbidity and mortality. Among the infections that fall in this 
category, aside from malaria, Mycobacterium tuberculosis (MTB) would be obvious. A MTB CHI 
model could provide a critical platform for the downselection of potential novel antibiotics as well as 
vaccine candidates. CHI studies with MTB are implausible because diagnosis is not straightforward, 
biocontainment difficult, routes of inoculation disputed (aerosolize vs skin) and treatment lengthy, 
associated with side effects and prone to failure. As a replacement for MTB infection, intradermal 
injections with the vaccine bacille Calmette-Guérin (BCG, attenuated Mycobacterium bovis) are 
tested as a surrogate CHI, followed by a punch biopsy 14 days after injection to investigate bacterial 
persistence and immune parameters.78 The low recovery of bacteria after CHI limits sensitivity of the 
model.79 However, prior vaccination with BCG did result in a decreased recovery rate of BCG after 
challenge, suggesting that the model is able to reveal protective immune effects.80 Besides the 
nature of the pathogen, another important limitation of the model is the dermal inoculation route as 
opposed to the natural inhalation of mycobacteria and therefore administration of aerosolized BCG 
or other (attenuated) mycobacterial strains are currently being investigated.81  
 Hookworm infections are one of the most prevalent neglected diseases for which only very limited 
number of anthelminthic drugs are available.86 These drugs are widely used and the concern for the 
development of resistance is growing. High reinfection rates indicate that vaccines with long-term 
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action are needed to effectively control or eventually eliminate these parasites.87 A number of 
vaccine candidates are undergoing early clinical testing.88 Necator americanus hookworm CHI can 
potentially contribute to go-no-go decisions for these vaccines. As animal models are lacking, 
hookworm larvae are cultured from faeces of chronically infected donors extensively screened for 
transmissible diseases such as HIV, HBV and HCV. Hookworm CHI has been performed in ~250 
volunteers in order to test whether hookworms, through induction of regulatory responses, can 
have therapeutic effects on inflammatory diseases such as celiac disease, IBD and allergic 
rhinosinusitis.89-92 Standardising the model, through achieving a stable egg output to serve as a 
reliable quantitative endpoint for vaccine efficacy testing, is the focus of current efforts and will 
prepare the model for evaluating candidate vaccine efficacy (NCT01940757).  
Following the example of hookworm, CHI models are being developed for two other parasitic 
diseases of global importance: schistosomiasis and cryptosporidium. Because parasites generally 
have a complex life cycle and may depend on multiple hosts for their maturation and development, 
the production of challenge material in compliance with all regulatory norms can be a daunting task. 
For Schistosoma mansoni an important conceptual step to ensure safety of CHI volunteers has been 
the propagation of single sex cercariae which can infect humans and mature to adult stage without 
mating. In single sex infections no eggs are produced, circumventing the pathology associated with 
chronic schistosomiasis caused by egg-induced granuloma formation and fibrosis. A highly sensitive 
diagnostic test based on circulating anodic antigen was crucial for the development of the model as 
it allows for accurate quantification of worm loads despite the lack of eggs.93 The first results of a 
Schistosoma mansoni CHI is expected soon (NCT02755324). The model will be suitable for testing 
new drugs and currently available vaccines such as Sm14, TSP2 and Smp80.94 However, anti-
fecundity vaccines or drugs that target egg laying, cannot be tested in these single sex infections.  
A recent evaluation of the causes of moderate-severe diarrhoea in children <2 years of age revealed 
Cryptosporidium as being the second or third leading pathogen. It is associated with malnutrition 
and enteropathy.95 This is why recent efforts have been put into reviving the pre-existing 
cryptosporidium CHI model96 to comply with 21st century regulations and serve the vaccine and drug 
development pipeline. Unfortunately, cryptosporidium cannot be cultured in vitro and is difficult to 
maintain in animal models. C. hominis cysts can only be produced by infection of gnotobiotic 
neonatal piglets. Considerable investments are now underway to allow purification of this material. 
However, culture of cysts without the need of animal models would be an important step forward 
for this model.  
 
Colonisation models 
Culture-independent technologies have revealed the diversity of the human microbiome.97 In an era 
of increasing antimicrobial resistance, the study of controlled colonisation in healthy volunteers has 
proven to be instrumental to dissect the dynamics of mucosal carriage of bacteria which precedes 
invasive bacterial infections. With regards to controlled colonisation, the upper respiratory tract 
microbiome has been the most studied. 
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The most frequently used model for colonisation is nasal instillation of S. pneumoniae, which leads 
to a roughly 50% colonization in healthy volunteers and lasts 2-5 weeks as confirmed by nasal 
washes.98-100 Interestingly, invasive pneumococcal disease has never been reported in studies of 
more than 800 inoculations performed so far. Despite the lack of clinical invasive disease, the model 
successfully predicted the efficacy of the 13-valent conjugate vaccine.101 This has paved the way for 
the use of the S. pneumoniae colonization model in testing new protein-based vaccines 
(NCT02116998). The model has also been instrumental in studying natural protection and the 
dynamics of the nasal microbiome.102-104 Strain specific immunity was induced by the controlled 
colonisation procedure, which was illustrated by a second challenge of volunteers with the same 
pneumococcal strain after 11 months.105 Analysing the immune responses indicated that high levels 
of memory B cells and antibodies directed to capsular pneumococcal polysaccharide seem to be key 
to protection against pneumococcal colonisation.106,107 Through the use of this model it was also 
possible to show that asymptomatic upper respiratory viral infections increase the risk of becoming 
colonized.108 The effect of the paediatric live attenuated influenza vaccine on pneumococcal carriage 
is subject of an ongoing controlled colonisation trial in adults (ISRCTN16993271). Nasal mucosa and 
lung investigations during this co-infection study might provide important insights into how 
influenza predisposes to secondary pneumococcus infections and thus lead to better interventions. 
These studies have also for the first time allowed the assessment of the impact of a viral vaccine on 
an entirely unrelated human pathogen, highlighting the need to consider off-target beneficial (or 
detrimental) effects of vaccines. Given the scientific advances and the favourable safety profile of 
the pneumococcal colonization model, the model has been expanded to explore the susceptibility of 
at-risk populations including people with asthma (ISRCTN16755478) and the elderly 
(ISRCTN10948363). 
In analogy to colonisation with pathogenic bacteria, it has been possible to deliberately colonize 
volunteers with non-pathogenic bacteria to investigate the effects on pathogen carriage.109,110  As an 
example, intranasal N. lactamica colonisation protects from colonisation by N. meningitides. The 
efficacy of this approach was shown to be superior to the commonly used quadrivalent ACWY 
glycoconjugate vaccine.110 Similarly, active colonisation of the bladder with non-pathogenic E. coli 
prevents urinary tract infections (UTI) in patients with recurrent UTIs.111-113 These trials were 
designed based on studies demonstrating that untreated asymptomatic bacteriuria prevents 
symptomatic urinary tract infection in young girls.114 The concept was further extended to vaginal 
instillation of lactobacilli in women with recurrent UTI, but results are much less convincing when 
compared to the E. coli colonisation model of the bladder.115 
More recent efforts include the development of colonization models with Nontypable Haemophilus 
influenzae and Bordetella pertussis. The H. influenzae model uses a challenge strain genetically 
modified to be streptomycin resistant which allows the investigators to efficiently recover the 
organism from the nasopharyngeal samples and achieve colonisation in 9/15 volunteers.116 Similar to 
CHI studies with the related organism Haemophilus ducreyi117, investigators hope to unravel the role 
of virulence factors in colonisation. The pertussis model is being established to increase our 
understanding of waning immunity after pertussis immunisation. It aims at achieving colonisation in 
70% of the exposed volunteers without causing disease and has a short inpatient period and follow 
up over one year.118  With procedures very similar to the previous colonisation models, efforts to 
develop a Group A Streptococcus pyogenes controlled infection model are underway but this model 
aims to induce  pharyngitis, and therefore it is formally not a model of colonisation but of disease.119 
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Colonisation models in principle do not reflect the pathophysiology of invasive disease, but the 
colonisation phase is increasingly recognised as an important target for vaccination. For example in 
pneumococcus, is the main source of transmission in the community. Vaccines which protect against 
colonisation will therefore have the potential to affect transmission.  Despite their non-invasive 
design, the risk of invasive disease in colonisation models cannot be completely averted. Controlled 
colonisation and infection models share many similarities such as the preparation of challenge 
material, inoculation routes and ethical considerations including the risk of dissemination of the 
challenge strain.  
 
Scientific advances  
CHI trials offer unprecedented opportunities to study host-pathogen interaction by taking multiple 
longitudinal samples before, during and after infection. Profiling immune parameters and linking 
those to the clinical outcome has shown to be extremely valuable in identifying correlates of 
protection. The availability of validated correlates of protection will accelerate the development of 
novel vaccines by providing an easier surrogate endpoint for phase 2 field trials. In addition, such 
insight may guide the refinement of vaccine products, for example through rational selection of 
adjuvants known to skew the immune response towards the preferred correlate, or the 
identification of novel vaccine targets. For example, in CHI models for salmonella,120 shigella,121 and 
norovirus122 antibodies were identified which, if present at baseline, correlated with protection from 
the challenge. Potentially, these antibodies could provide clues for novel monoclonal antibody-based 
therapy or lead to the identification of functional antigens. Similarly, a study of peripheral 
mononuclear blood cells of volunteers in a rhinovirus CHI study using MHC class II tetramers has led 
to the identification of specific memory T-cell populations that rapidly respond to infection and 
target conserved epitopes of the rhinovirus capsid proteins.123 These epitopes will be subject of 
further research into their potential use as novel peptide vaccines.  
Repeated CHI in the same individuals contributes to understanding the induction of natural 
immunity. A gradual decrease in the number of people reaching the endpoint is generally a sign of 
slowly acquired natural immunity, as was seen for shigella,124 BCG,80 cholera,125 norovirus,126 
pneumococcus,105 and enterotoxigenic E. coli.127 This was not the case in RSV CHI, where previously 
protected individuals can again be susceptible after the next inoculation, indicating that naturally 
acquired immunity in RSV is transient.128 Dissection of the humoral responses in these subjects 
revealed a defect in virus-specific IgA memory B-cells128, which identifies a pathway that can serve to 
develop a vaccine.  
Other examples of discoveries made with CHI include the importance of blood group in norovirus 
infection. Individuals with an O blood group have increased susceptibility for norovirus while those 
with a B histo-blood group show a decreased risk of infection.129 Interestingly, in infection with V. 
cholera volunteers with O blood group also suffered from more severe symptoms.130 Because blood 
group and other related carbohydrate antigens are highly expressed on gut epithelial cells, their 
involvement in viral or bacterial docking is suspected. Indeed the H type-1 oligosaccharide ligand (a 
member of the ABH blood group family) was found to be critical for Norwalk virus binding.129   
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It is important to note that CHI can also serve an early signalling of differences that might affect the 
phase III testing in pre exposed populations in endemic regions. The comparison of different 
populations in controlled infection trials is providing insight into heterogeneity in terms of the 
overall efficacy of the product when distributed widely in the target population.  
 
In order to fully understand the complex interplay between genetic background, diet, microbiome, 
co-infections and previous exposure in determining clinical outcome after CHI, comprehensive 
system biology approaches are required. Recently orthogonal datasets including transcriptomics, 
immunologic parameters as well as metabolomics signatures to zostavax, a live attenuated vaccine, 
were integrated and showed reactivation of networks that are tightly coupled with T- and B-cell 
responses.131 Interestingly, such network analysis generated novel insights into the endocrine 
system as well as metabolomics playing a role in vaccine responses.  These tools can now be applied 
to CHI in the context of both vaccine and drug development.  
 
 
Future challenges and opportunities  
The increasing costs for clinical development of novel drugs and vaccines for infectious diseases calls 
for tools to select those candidates with highest probability of success. The concept of “fast failure”, 
in which there is an early stop for the development of unsuccessful candidates is extremely 
important as it will allow reallocation of resources. CHI studies may be used as model for phase 2 
clinical efficacy. As such they may reduce development risk, lower overall costs and increase risk-
adjusted net present value. Especially in poverty-related infectious disease research, cost-effective 
development of novel interventions is imperative. Despite the advantages of CHI in clinical 
development, these studies also have disadvantages. Particularly the use of a “surrogate” inoculum 
or volunteers which are much different from the target population poses significant limitations. As 
such, CHI will not resolve all problems in clinical development but, whenever possible, should be put 
to use as an accelerating tool.   
 
Because of their often invasive nature and the use of healthy volunteers CHI trials continue to raise 
ethical debate amongst public, Institutional Review Boards (IRBs) and investigators.132 The fear of 
long-term adverse effects such as reactive arthritis or post-infectious irritable bowel syndrome in 
Shigella or enterotoxicogenic E. coli infections are well known examples.124 Quantitative risk data is 
needed to facilitate objective risk assessments, which need to be tailored to individual models and 
research targets. Currently, the lack of standardized reporting of adverse events and in particular 
serious adverse events as well as inoculation route, dose and timing of events hamper the meta-
analysis of available safety data. Similarly, data on possible spread or secondary infections with 
challenge strain should be made publicly available to indicate the need for quarantine of subjects 
with gastrointestinal or respiratory infections. Easily accessible standardized safety data on CHI 
studies will also facilitate the evidence-based establishment or adjustment of CHI regulations and 
increase the expertise of IRBs in this domain. 
 
A major hurdle in the development of novel CHI models is often the production of challenge 
inoculum compliant with regulations, which may be difficult, expensive and time consuming. In 
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addition, regulatory requirements may vary across different continents. Public-private partnerships, 
funders and consortia of CHI researchers should share the responsibility for investing in sustainable, 
widely available, well-characterized master banks of this material and define the quality control 
assays that are believed to be essential for volunteers safety. In addition, the open sharing of 
knowledge and infrastructure would support best practices and provide a knowledge base for CHI 
model transfer and capacity building.  
 
In conclusion, CHI models are emerging as powerful tools to down select promising new vaccines or 
drugs on their increasingly complex and expensive path towards licensure. Despite their invaluable 
contribution to science and product development, the demanding nature of CHI trials and risks 
involved requires careful risk-benefit assessments in which the safety of participants should be a 
primary concern at all times. 
Search strategy and selection criteria 
References were identified in PubMed using the search terms ("experimental infection*" OR "human 
challenge" OR "challenge study" OR "challenge model" OR "human infection" OR “infection model” 
OR “volunteer study” OR “infection in volunteers” OR “volunteer challenge” OR “controlled human 
infection”), separately combined with each pathogen listed in the table. For each pathogen the 
Mesh-term was combined with an [All Fields] search of common synonyms.  We searched for articles 
published between Jan 1, 1900 and 1 October 2017. Only articles in English, French or Dutch were 
reviewed. The references of reviews and key publications were searched to identify any other 
references. Only studies using pathogens to experimentally infect humans were included. Studies 
using an attenuated pathogen for the sole purpose of vaccination were not included in the 
estimation of total volunteer numbers. Articles were the total number of volunteers in the study 
could not be identified were not included in estimate of total volunteer numbers but were included 
in the estimation of total studies.  
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Figure legends 
Figure 1: Graphic representation of the risk of failure and the risk-adjusted net-present value 
(rNPV) of a product before (light red) and after (dark red) introduction of a CHI model. The CHI 
model will increase the risk of failure in the early stage of clinical development, but reduce it at a 
later stage. Because the risk distribution shifts towards higher risks in the early stages of 
development, the risk-adjusted net present value (rNPV) of the product will increase. As such, the 
increased initial investments in the CHI models are returned through increased rNPV. 
Figure 2: Numbers of volunteers in CHI trials. (A) Estimated number of CHI trials reported per 
decade for rhinovirus (blue), influenza (red), P. falciparum (green) and other (black) infections. (B) 
Estimated mean number of volunteers per trial for CHI models with different pathogens. Generally, 
the number of volunteers per trial increases as the efficiency with which the endpoint is achieved 
decreases (e.g. 50 vs 100% infection rates) (C) Estimated cumulative number of volunteers 
previously experimentally infected in a CHI trial per pathogen, reported from 1900. Total number 
estimated at around 22.000 volunteers. All estimations are based on numbers available in published 
literature. 
 
Tables 
 
Pathogen Route Dose Strain End points Est. # 
volunt
eers 
In/outpatie
nt/ 
isolation 
Ref 
Rhinovirus intranasal 10.000 
TCID50  
HRV-16, 
HRV-39 
viral 
replication, 
clinical 
symptoms 
5760 outpatient 24 
Influenza 
virus 
intranasal 103-107  
TCID50 
* viral shedding 
in nasal 
lavage, clinical 
symptoms 
3540 in patient 
quarantine 
2 
Plasmodium 
falciparum 
mosquitos, 
intravenou
s 
5 mosquitos, 
3200pfSPZ 
NF135.10, 
NF54 
parasitemia 2650 outpatient 39,42 
ETEC oral ≥ 5x108 CFU  B7A, 
H10407, 
E24377A 
diarrhoea 1215 outpatient 133 
Vibrio 
cholerae 
oral 105 CFU  El Tor Inaba 
N16961, 
O139 
diarrhoea 1210 inpatient 8,134 
Salmonella 
Typhi 
oral 1-5x104 CFU  Quailes  fever or 
bacteraemia 
1000 outpatient 135 
Respiratory 
syncytial 
virus 
intranasal  4log10 
PFU/ml 
M37, A2 viral load in 
nasal lavage, 
respiratory 
symptoms 
1000 in patient 
quarantine 
136 
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Shigella spp oral 10 CFU – 
1010 CFU  
S. flexneri 
2457T, S. 
sonnei 53G 
diarrhoea, 
antibody 
response 
850 inpatient 124 
Norovirus oral 48 RT-PCR U 8FIIa, GI.1, 
GII.4 
gastro-
enteritis, PCR 
faeces, ELISA 
810 inpatient 71,137 
Lactobacillus 
spp 
oral, 
vaginal 
oraal 109 
CFU 1dd, 
7.5x108 CFU 
subs 
L. rhamnosis 
GR-1, L. 
reuteri RC-
14, L. 
crispatus 
CTV05 
clinical UTI 800 outpatient 115 
Streptococcu
s 
pneumoniae 
intranasal 105-106 CFU  6B, 23F colonisation  790 outpatient 100 
Haemophilus 
ducreyi 
Intraepider
mal and 
intradermal 
10-150 CFU 35000HP pustule 
formation 
550 outpatient  
Dengue virus subcutaneo
usly 
103 PFU  DEN2Δ30 viremia, rash, 
neutropenia 
520 outpatient/ 
inpatient 
4 
Francisella 
tularensis 
aerosol 104-108 
organisms 
SCHU S4 systemic 
symptoms 
500 inpatient 139 
Neisseria 
lactamica 
intranasal 104 CFU  Y92-1009 colonisation 310 outpatient 110 
Plasmodium  
vivax 
mosquitos, 
intravenou
s 
5 mosquitos, 
3200 pFSPZ 
wild-type  parasitemia 300 outpatient 140 
Campylobact
er jejuni 
oral 106-109 CFU initially 81-
176, now 
CG8421 
diarrhoea 260 inpatient 141 
Cryptosporid
ium spp 
oral 10-105 
oocysts 
** stool oocysts 260 outpatient 96,142 
Necator 
americanus 
Transderm
al 
10-50L3 
larvae 
Papua New 
Guinea 
Eggs in stool 250 outpatient 89 
Escherichia 
coli (UTI) 
Urethral 
catheter 
105-106/ml 83792, 
HU2117 
clinical UTI 200 outpatient 109 
BCG intradermal 1-4x105 CFU  BCG immune 
response 
140 outpatient 80 
Neisseria 
gonorrhoea 
urethral 
catheter 
1,8x103 
Ms11mkC, 
1.0x105 
FA1090 
FA1090, 
MS11mkC 
colonisation 140 outpatient 143 
Giardia 
lamblia 
oral 5-104 
trophozoites 
GS-M83/85 cysts in stool, 
antibody 
response 
120 inpatient 144 
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Helicobacter 
pylori 
oral 104 CFU Baylor 100 urea breath 
test, histology 
80 outpatient 145 
Salmonella 
Paratyphi 
oral 1-5x103 CFU  NVGH308 
strain 
fever or 
bacteraemia 
40 outpatient 146 
Parvovirus 
B19 
nasal Up to 510 
viral 
genomes 
Wild-type viremia 12 Inpatient 
isolation 
147 
 
 
 
Table 1: Summary of characteristics per CHI model based on published data. Most commonly used 
strains are reported, number of volunteers is estimated from publications. 
ETEC= Enterotoxicogenic Escherichia choli, Salmonella Typhi/Paratyphi = Salmonella enterica subsp. 
enterica serovar Typhi 
 
 
* A/Texas/39/91 (H1N1), A/California/2009 (H1N1), A/Winsonsin/67/2005 (H3N2) 
** C. muris: RN66, C. meleagridis: TU1867, C. hominis: Iowa strain, C. parvum: Iowa strain 
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